Atlas Trials

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Clinical trial NCT05873790 · UNKNOWN

Trial details

NCT number
NCT05873790
Sponsor
The First Hospital of Jilin University
Status
UNKNOWN
Study type
OBSERVATIONAL
Lung Cancer
Start date
2023-06-01
Primary completion
2024-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.